Chemokine Receptor Modulation for Parkinson's Disease

Migration, Crosslink

📖

Chemokine Receptor Modulation for Parkinson's Disease

active

wiki page Created: 2026-04-02T07:19:01 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-chemokine-receptor-mod

📖 Wiki Page

therapeutic1744 wordssynced 2026-04-02

Chemokine Receptor Modulation for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Chemokine Receptor Modulation for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Chemokine Axis</td>
<td>Change in PD</td>
</tr>
<tr>
<td class="label">CX3CL1/CX3CR1</td>
<td>↓ Soluble CX3CL1</td>
</tr>
<tr>
<td class="label">CCL2/CCR2</td>
<td>↑ CCL2 in CSF</td>
</tr>
<tr>
<td class="label">CCL3-5/CCR5</td>
<td>↑ CCL5 in SN</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Company</td>
</tr>
<tr>
<td class="label">CX3CL1 recombinant</td>
<td>Various</td>
</tr>
<tr>
<td class="label">CX3CR1 agonist (oral)</td>
<td>To be determined</td>
</tr>
<tr>
<td class="label">AAV-CX3CL1</td>
<td>Gene therapy companies</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Company</td>
</tr>
<tr>
<td class="label">PF-04136309</td>
<td>Pfizer</td>
</tr>
<tr>
<td class="label">CCX872</td>
<td>ChemoCentryx</td>
</tr>
<tr>
<td class="label">RS504393</td>
<td>Roche</td>
</tr>
<tr>
<td class="label">MLN1202</td>
<td>Millennium/Takeda</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Maraviroc</td>
<td>ViiV Healthcare</td>
</tr>
<tr>
<td class="label">Cenicriviroc</td>
<td>Allergan/Tobira</td>
</tr>
<tr>
<td class="label">Vicriviroc</td>
<td>Merck</td>
</tr>
<tr>
<td class="label">Pati

...

Chemokine Receptor Modulation for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Chemokine Receptor Modulation for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Chemokine Axis</td>
<td>Change in PD</td>
</tr>
<tr>
<td class="label">CX3CL1/CX3CR1</td>
<td>↓ Soluble CX3CL1</td>
</tr>
<tr>
<td class="label">CCL2/CCR2</td>
<td>↑ CCL2 in CSF</td>
</tr>
<tr>
<td class="label">CCL3-5/CCR5</td>
<td>↑ CCL5 in SN</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Company</td>
</tr>
<tr>
<td class="label">CX3CL1 recombinant</td>
<td>Various</td>
</tr>
<tr>
<td class="label">CX3CR1 agonist (oral)</td>
<td>To be determined</td>
</tr>
<tr>
<td class="label">AAV-CX3CL1</td>
<td>Gene therapy companies</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Company</td>
</tr>
<tr>
<td class="label">PF-04136309</td>
<td>Pfizer</td>
</tr>
<tr>
<td class="label">CCX872</td>
<td>ChemoCentryx</td>
</tr>
<tr>
<td class="label">RS504393</td>
<td>Roche</td>
</tr>
<tr>
<td class="label">MLN1202</td>
<td>Millennium/Takeda</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Maraviroc</td>
<td>ViiV Healthcare</td>
</tr>
<tr>
<td class="label">Cenicriviroc</td>
<td>Allergan/Tobira</td>
</tr>
<tr>
<td class="label">Vicriviroc</td>
<td>Merck</td>
</tr>
<tr>
<td class="label">Patient Profile</td>
<td>Primary Target</td>
</tr>
<tr>
<td class="label">Early PD, high neuroinflammation</td>
<td>CCR2/CCR5</td>
</tr>
<tr>
<td class="label">Advanced PD, microglia-dominated</td>
<td>CX3CR1</td>
</tr>
<tr>
<td class="label">Rapid progression</td>
<td>Dual CCR2/CCR5 (Cenicriviroc)</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Proposed PD Dose</td>
</tr>
<tr>
<td class="label">Maraviroc</td>
<td>300mg BID</td>
</tr>
<tr>
<td class="label">Cenicriviroc</td>
<td>250-500mg daily</td>
</tr>
<tr>
<td class="label">CX3CR1 agonist</td>
<td>TBD</td>
</tr>
</table>

Chemokine receptor modulation represents a promising immunotherapeutic strategy for Parkinson's disease (PD), targeting the neuroinflammatory processes that drive dopaminergic neuron loss. The chemokine system—particularly the CX3CL1/CX3CR1, CCL2/CCR2, and CCL3-5/CCR5 axes—plays a critical role in microglial recruitment, peripheral immune cell infiltration, and the maintenance of neuron-microglia communication. Dysregulation of these pathways contributes to chronic neuroinflammation in PD, making them attractive therapeutic targets.

This page covers three major chemokine receptor systems relevant to PD:

CX3CR1 — The fractalkine receptor that mediates neuron-to-microglia signaling

CCR2 — The receptor for CCL2 (MCP-1) that drives monocyte recruitment

CCR5 — The receptor for CCL3-5 (MIP-1α/β, RANTES) that mediates neurotoxic inflammation

Pathophysiological Context

Neuroinflammation in PD

In Parkinson's disease, neuroinflammation is both a consequence and driver of dopaminergic neurodegeneration. Key features include:

Early microglial activation: Iba1+ microglia show increased density in substantia nigra before motor symptoms
Peripheral immune infiltration: CD4+ and CD8+ T-cells infiltrate the substantia nigra
Pro-inflammatory cytokine surge: TNF-α, IL-1β, and IL-6 are elevated in CSF and brain tissue
Blood-brain barrier disruption: Permits monocyte entry and amplifies inflammation

Chemokine Dysregulation

CX3CR1 Modulation

Biological Basis

CX3CR1 is expressed almost exclusively on microglia in the central nervous system, making it an ideal target for CNS-directed immunomodulation. The CX3CL1 (fractalkine)-CX3CR1 axis functions as:

Neuroprotective signaling: Neurons secrete CX3CL1, which signals through microglial CX3CR1 to maintain surveillance state
Anti-inflammatory tone: CX3CR1 activation typically promotes anti-inflammatory microglial phenotypes
Phagocytosis regulation: The axis modulates microglial clearance of debris without excessive activation

Evidence in PD

Preclinical evidence:

CX3CR1 deficiency exacerbates dopaminergic neuron loss in α-synuclein transgenic mice[@moehle2023]
CX3CR1 deficiency worsens α-synuclein pathology and motor dysfunction
CX3CL1 overexpression protects substantia nigra pars compacta neurons[@pabon2023]
CX3CL1 gene therapy reduces microglial activation and improves survival in PD models[@castrosnchez2023]

Key findings:

CX3CR1 haploinsufficiency (common in humans, ~30% carry the V64I variant) increases PD risk
CX3CR1 signaling modulates NLRP3 inflammasome activity in microglia
The axis regulates complement-mediated synapse elimination

Therapeutic Approaches

CX3CR1 agonists: Recombinant CX3CL1, engineered fractalkine domains, small molecule agonists

CX3CL1 mimetics: Synthetic analogs with enhanced stability

Gene therapy: AAV-mediated CX3CL1 expression

Clinical Development Status

Challenges:

Blood-brain barrier penetration
Balancing anti-inflammatory effects with host defense
Dosing optimization for chronic dosing

CCR2 Antagonism

Biological Basis

CCR2 is the primary receptor for CCL2 (monocyte chemoattractant protein-1, MCP-1), CCL7, CCL8, and CCL13. In PD:

Peripheral monocytes: CCR2+ monocytes are recruited to the CNS via CCL2 gradients
Microglial proliferation: CCR2 signaling drives microglial activation and proliferation
Pro-inflammatory amplification: Infiltrating monocytes amplify the inflammatory response

Evidence in PD

Preclinical evidence:

CCR2 antagonism reduces dopaminergic neuron loss in MPTP and 6-OHDA models[@thome2024]
CCL2 levels are elevated in PD CSF and correlate with disease severity[@gonzalez2024]
CCR2 knockout mice show reduced microglial activation and protected neurons
Blocking CCL2-CCR2 signaling decreases peripheral immune cell infiltration

Therapeutic Approaches

Small molecule CCR2 antagonists: PF-04136309, CCX872, RS504393

Monoclonal antibodies: MLN1202

RNA antagonists: CCR2-targeting siRNA

Clinical Development Status

Challenges:

CCR2 antagonists have primarily been developed for oncology (PF-04136309)
Brain penetration is limited for most candidates
Must balance blocking harmful infiltration with host defense

CCR5 Antagonism

Biological Basis

CCR5 is the receptor for CCL3 (MIP-1α), CCL4 (MIP-1β), and CCL5 (RANTES). In PD:

Microglial activation: CCR5 on microglia drives pro-inflammatory responses
T-cell recruitment: CCR5-CCL5 axis recruits CD4+ and CD8+ T-cells to the substantia nigra
Neurotoxic inflammation: CCR5 activation contributes to dopaminergic neuron toxicity

Evidence in PD

Preclinical evidence:

CCR5 blockade reduces neuroinflammation in α-synuclein models[@barbuti2024]
CCR5 antagonists protect dopaminergic neurons in multiple PD models
CCL5 is elevated in PD substantia nigra and CSF
CCR5 deficiency reduces microglial activation and improves motor function

Therapeutic Approaches

Maraviroc: FDA-approved HIV drug, being repurposed for AD/PD

Cenicriviroc: Dual CCR2/CCR5 antagonist in Phase II for AD

Vicriviroc: CCR5 antagonist with CNS penetration potential

Clinical Development Status

Dual CCR2/CCR5 Antagonism

Cenicriviroc (CVC) is the most advanced dual antagonist for neurodegenerative disease:

Rationale

Broader coverage: Blocks both monocyte recruitment (CCR2) and T-cell infiltration (CCR5)
Synergistic effects: More effective than single-receptor blockade in preclinical models
Single agent: Simplifies clinical development

Clinical Status

COMPLETED: Phase II trial in Alzheimer's disease (NCT02328872)
PLANNED: Trials in Parkinson's disease

Key Efficacy Signals

Reduced CSF inflammatory markers in AD trial
Good safety and tolerability profile
Once-daily oral dosing

Integrated Therapeutic Strategy

Target Selection by Patient Population

Combination Approaches

CX3CR1 agonist + CCR5 antagonist: Combine neuroprotective signaling with inflammation reduction

CCR2 antagonist + disease-modifying therapy: Immunomodulation + α-synuclein targeting

Triple approach: CX3CR1 + CCR2 + CCR5 modulation

Biomarkers for Patient Selection

Enrichment markers: Elevated CSF CCL2, CCL5, or YKL-40
TSPO PET: Active microglial activation in substantia nigra
Peripheral markers: Monocyte count, cytokine panel

Molecular Mechanisms

Mermaid diagram (expand to render)

Clinical Trial Considerations

Trial Design Recommendations

Patient population: Early PD (Hoehn & Yahr 1-2) with elevated inflammatory markers

Enrichment: Require elevated CSF CCL2, CCL5, or YKL-40 at baseline

Endpoints:

Primary: Change in MDS-UPDRS at 52 weeks
Secondary: CSF inflammatory markers, TSPO PET, dopamine transporter imaging

4. Duration: Minimum 52 weeks for disease modification signals

Recommended Doses

Safety Considerations

CX3CR1 Agonists

Peripheral immune effects: CX3CR1 affects monocyte trafficking
Infection risk: Chronic immunomodulation may increase susceptibility
Reproductive effects: CX3CR1 knockout mice show subtle defects

CCR2/CCR5 Antagonists

Liver function: Some antagonists cause elevated transaminases
Drug interactions: Maraviroc requires CYP3A4 consideration
Immunosuppression: Potential increased infection risk
Long-term safety: Unknown in chronic neurodegenerative disease

Monitoring Recommendations

Liver function tests monthly
Infection surveillance
Immunophenotyping ( peripheral immune cell counts)
CSF inflammatory markers at baseline and endpoint

Research Gaps

Human genetics: Validate CX3CR1 variant effects on PD progression

Biomarker development: CSF chemokines as predictive markers

Brain penetration: Develop CNS-penetrant CCR2 antagonists

Combination approaches: Synergy with α-synuclein-targeted therapies

Dosing optimization: Chronic vs. intermittent dosing

References

[Bachiller S, et al., The CX3CL1/CX3CR1 axis in CNS disease. Mol Neurodegener. 2023;18(1):47 (2023)](https://doi.org/10.1186/s13024-023-00636-1)

[Moehle MS, et al., CX3CR1 deficiency worsens α-synuclein pathology. Brain. 2023;146(7):2862-2877 (2023)](https://doi.org/10.1093/brain/awad053)

[Castro-Sánchez S, et al., CX3CR1 modulates neuroinflammation in PD. J Neuroinflammation. 2023;20(1):89 (2023)](https://doi.org/10.1186/s12974-023-01787-6)

[Pabon MM, et al., CX3CL1 gene therapy protects dopaminergic neurons. Mol Ther. 2023;31(6):1618-1631 (2023)](https://doi.org/10.1016/j.ymthe.2023.03.022)

[Thome T, et al., CCR2/CCR5 antagonism preserves dopaminergic neurons in PD models. Neurobiology of Disease. 2024;190:105838 (2024)](https://doi.org/10.1016/j.nbd.2024.105838)

[Villoslada P, et al., Chemokine receptor targeting in neurodegenerative disease. Nat Rev Drug Discov. 2024;23(2):115-133 (2024)](https://doi.org/10.1038/s41573-023-00756-5)

[Morganti JM, et al., T cell infiltration correlates with reduced CX3CR1 in Parkinson's disease. J Neurosci. 2023;43(12):2134-2145 (2023)](https://doi.org/10.1523/JNEUROSCI.1822-22.2023)

[Barbuti PA, et al., CCR5 blockade reduces neuroinflammation in alpha-synuclein models. Mov Disord. 2024;39(5):723-734 (2024)](https://doi.org/10.1002/mds.297)

[Gandhi R, et al., CX3CR1 agonists for Parkinson's disease: translational considerations. Pharmacol Res. 2024;199:106984 (2024)](https://doi.org/10.1016/j.phrs.2024.106984)

[Gonzalez A, et al., Monocyte trafficking in Parkinson's disease: the CCR2-CCL2 axis. Brain. 2024;147(3):1023-1035 (2024)](https://doi.org/10.1093/brain/awad372)

Actionable Next Steps

Lab Experiments

CX3CR1 agonist screening: Identify brain-penetrant CX3CR1 agonists

Biomarker validation: Validate CSF CCL2, CCL5 as patient selection markers

Combination testing: Test CX3CR1 agonist + CCR5 antagonist in α-synuclein models

Clinical Protocol Design

Enrichment strategy: Select patients with elevated CSF inflammatory markers

Dose-finding: Establish maximum tolerated dose with brain exposure

Endpoint selection: Use MDS-UPDRS + CSF biomarkers + TSPO PET

Company Partnership Opportunities

Pfizer: Has CCR2 antagonist PF-04136309

ViiV Healthcare: Maraviroc for HIV, potential CNS indications

Allergan/Tobira: Cenicriviroc dual antagonist

Academic centers: Movement disorder centers with neuroinflammation focus

Implementation Roadmap

Phase 1: Target Validation (Months 1-12)

Activities: Biomarker validation, preclinical combination studies
Cost: $2-4M
Go/No-Go: Identify lead indication and patient population

Phase 2: Clinical Development (Months 12-36)

Activities: Phase 1/2 trial in early PD
Cost: $10-20M
Go/No-Go: Safety signal, biomarker modulation

Phase 3: Registration (Months 36-60)

Activities: Pivotal trial
Cost: $25-40M
Endpoints: MDS-UPDRS, biomarker endpoints

Total Program Cost: $37-64M over 60 months

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Fractalkine Axis Amplification via CX3CR1 Positive Allosteric Modulators](/hypothesis/h-ba3a948a) — 0.63 · Target: CX3CR1
[Optogenetic Microglial Deactivation via Engineered Inhibitory Opsins](/hypothesis/h-782b40b1) — 0.54 · Target: CX3CR1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — 0.71 · Target: GLP1R, BDNF
[Lysosomal Calcium Channel Modulation Therapy](/hypothesis/h-8ef34c4c) — 0.68 · Target: MCOLN1
[Metabolic Circuit Breaker via Lipid Droplet Modulation](/hypothesis/h-3d993b5d) — 0.66 · Target: PLIN2

Related Analyses:

[Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
[Perivascular spaces and glymphatic clearance failure in AD](/analysis/SDA-2026-04-01-gap-v2-ee5a5023) 🔄
[Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄
[Tau propagation mechanisms and therapeutic interception points](/analysis/SDA-2026-04-02-gap-tau-prop-20260402003221) 🔄
[What are the mechanisms by which gut microbiome dysbiosis influences Parkinson's disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-chemokine-receptor-modulation-parkinsons

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-chemokine-receptor-modulation-parkinsons
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-f2978500ba91
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-chemokine-receptor-modulation-parkinsons'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

104

Outgoing

119

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Chemokine Receptor Modulation for Parkinson's Disease

Chemokine Receptor Modulation for Parkinson's Disease

Overview

Chemokine Receptor Modulation for Parkinson's Disease

Overview

Pathophysiological Context

Neuroinflammation in PD

Chemokine Dysregulation

CX3CR1 Modulation

Biological Basis

Evidence in PD

Therapeutic Approaches

Clinical Development Status

CCR2 Antagonism

Biological Basis

Evidence in PD

Therapeutic Approaches

Clinical Development Status

CCR5 Antagonism

Biological Basis

Evidence in PD

Therapeutic Approaches

Clinical Development Status

Dual CCR2/CCR5 Antagonism

Rationale

Clinical Status

Key Efficacy Signals

Integrated Therapeutic Strategy

Target Selection by Patient Population

Combination Approaches

Biomarkers for Patient Selection

Molecular Mechanisms

Clinical Trial Considerations

Trial Design Recommendations

Recommended Doses

Safety Considerations

CX3CR1 Agonists

CCR2/CCR5 Antagonists

Monitoring Recommendations

Research Gaps

See Also

References

Actionable Next Steps

Lab Experiments

Clinical Protocol Design

Company Partnership Opportunities

Implementation Roadmap

Phase 1: Target Validation (Months 1-12)

Phase 2: Clinical Development (Months 12-36)

Phase 3: Registration (Months 36-60)

Related Hypotheses

💬 Discussion